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Background: Guideline bodies recommend less strict glycaemic targets in older people with diabetes. 
It is uncertain whether the benefits of deintensification or de-prescribing, commonly employed by 
clinicians to achieve the less strict targets, outweighs the harms in these patients. We conducted a 
systematic review of published evidence, to assess deintensification approaches and rates and evaluate 
the harms and benefits of deintensification with antidiabetic medication and other therapies amongst 
older people (≥ 65 years) with type 2 diabetes with or without cardiometabolic conditions.  
Methods: We identified relevant studies in a literature search of MEDLINE, Embase, Web of 
Science, and Cochrane databases to 30 October 2018. Data was extracted on baseline characteristics, 
details on deintensification, and outcomes and was synthesized using a narrative approach. 
Results: Ten studies (observational cohorts and interventional studies) with data on 26,558 patients 
with comorbidities were eligible. Deintensification approaches included complete withdrawal, 
discontinuation, reducing dosage, conversion, or substitution of at least one medication, but majority 
of studies were based on complete withdrawal or discontinuation of antihyperglycaemic medication. 
Rates of deintensification approaches ranged from 13.4% to 75%. Majority of studies reported no 
deterioration in HbA1c levels, hypoglycaemic episodes falls or hospitalisation on deintensification. 
On adverse events and mortality, no significant differences were observed between the comparison 
groups in the majority of studies.  
Conclusion: Available but limited evidence suggests that the benefits of deintensification outweighs 
the harms in older people with type 2 diabetes with or without comorbidities. Given the heterogeneity 
of patients with diabetes, further research is warranted on which deintensification approaches are 
appropriate and beneficial for each specific patient population. 
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Type 2 diabetes is a chronic disease which is characterized by high levels of blood glucose 
(hyperglycaemia). It is one of the major causes of death globally.1 Most patients with type 2 diabetes 
have at least one complication, which include cardiovascular disease (CVD), stroke, chronic kidney 
disease (CKD), retinopathy, and neuropathy.2 Cardiovascular complications are the leading cause of 
morbidity and death in these patients.1   
 
The major goal of managing type 2 diabetes is to achieve appropriate reduction in glucose levels, in 
order to minimize the risk of complications, which include adverse vascular events.3 To achieve 
appropriate glycaemic targets as set by guideline bodies, antihyperglycaemic medications are usually 
initiated individually or in combination 4 in a timely manner when appropriate to prevent therapeutic 
inertia defined as the failure to advance treatment by a healthcare professional when appropriate to do 
so.5 At the same time, there needs to be a balance between the relative risks of clinical inertia (i.e., the 
failure to deintensify therapy when appropriate to do so) versus overtreatment in the management of 
glycaemia in patients with diabetes.6 In older patients with type 2 diabetes, achieving glycaemic 
control is very problematic; with adverse effects such as hypoglycaemia reported to be common in 
such patients.7,8 Consequencies of hypoglycaemia impacts substantially on patients and the healthcare 
system – these include physical injury, psychological harm, impaired cognition, reduced quality of 
life, mortality, additional manpower and resource utilization and costs of providing emergency 
assistance.9-14 Majority of older type 2 diabetes patients have co-existing frailty and comorbidities 
such as renal and cognitive impairment and the risk of hypoglycaemia is particularly high in these 
patients.7,9,15  Despite recommendations by guideline bodies to individualise glycaemic targets with 
risk assessments aimed at avoiding overtreatment and hypogycaemia,16-18 recent data suggest 
increased hospital emergencies for hypoglycaemia.19 Indeed, evidence suggests that older people with 
complex multiple comorbidities are being overtreated with drugs that cause hypoglycaemia.20-22 





in older patients outweigh the benefits,20 data on the potential benefits and harms of stopping, 
reducing, or substituting these antihyperglycaemic agents (i.e., deintensification) in the older patients 
with type 2 diabetes and comorbidities remains uncertain. Deintensification as defined by a position 
statement from Primary Care Diabetes Europe, is the de-escalation or down-titration of glucose-
lowering therapy by reducing the dose, deprescribing or substituting one agent for a less potent 
glucose-lowering therapy.23 Deintensification also includes deprescribing, which is the process of 
withdrawal or stopping inappropriate medication and the ultimate goal is improving outcomes and 
managing polypharmacy.24,25  Deintensification approaches are on the increase and it is becoming an 
established part of the prescribing process, especially in the management of older patients with 
multiple comorbidities.26,27 There is emerging evidence on the efficacy of deintensification from 
several randomised trials and observational studies conducted in other patient populations.25 In older 
patients with type 2 diabetes with or without comorbidities, it is uncertain whether the benefits of 
deintensification outweighs the harms in these patients. In this context, using a systematic review of 
all available published observational and interventional evidence, our primary aim was to assess 
deintensification approaches and rates and evaluate the harms and benefits of deintensification with 
antidiabetic medication and other therapies amongst older people (≥ 65 years) with type 2 diabetes 
with or without other cardiometabolic conditions such as CVD, CKD, or dementia. Given that 
majority of these patients are also on non-diabetic medication (e.g., lipid lowering drugs, 
antihypertensives) for their comorbidities, we also included these medications in our evaluation. We 




A predefined protocol was used to conduct this review and also in accordance with PRISMA and 
MOOSE guidelines 28,29 (Appendix 1-2) and using a protocol, which has been registered in the 





observational (cross-sectional, prospective or retrospective case control, prospective cohort, 
retrospective cohort, case-cohort, or nested-case control) studies and clinical trials (randomised 
controlled trials (RCTs) including cluster and pragmatic trials and non-randomised controlled trials) 
that had reported on (i) older patients (≥ 65 years) with type 2 diabetes with or without co-existing 
cardiometabolic conditions such as CVD, CKD, or dementia who were taking antidiabetic medication 
with or without other therapies for their conditions; (ii) reported deintensification approaches 
(stopping drug treatment entirely, reducing dose, gradual tapering, or substitution); and/or (iii) 
reported outcomes such as measures of glycaemia, admission rates, hospitalisations, complications, 
mortality, quality of life, and patient satisfaction. The age cut off applied if the average age of study 
participants age was 65 years or older; more than 75% of study participants were aged 65 years and 
older; or ability to extract data on participants aged 65 years and older from the study. The following 
exclusions were applied (i) studies not reporting deintensification approaches; (ii) those not including 
patients with type 2 diabetes; (iii) those including patients < 65 years; or (iv) studies that included 
only terminal or palliative patients. 
 
Definition of terms 
Based on the PICO (Population, Intervention, Comparator, and Outcome) framework, the population 
included older patients (≥ 65 years) with type 2 diabetes with or without co-existing cardiometabolic 
conditions such as CVD, CKD, or dementia, who were taking antidiabetic medication with or without 
other therapies for their conditions. The intervention was a deintensification rate, defined as the 
proportion of patients for whom one medication was stopped, reduced, or switched [(n/N)*100], 
where n denotes number of patients stopping, reducing, or switching medication and N refers to the 
total number of patients. The comparator included usual care or continuing medications. Outcomes 
included measures of glycaemia, admission rates, hospitalisations, complications, mortality, quality of 






Data sources and search strategy 
We searched MEDLINE, Embase, Web of Science, and Cochrane databases from inception to 
October 2018. The computer-based searches combined free and MeSH search terms and combination 
of key words related to diabetes and other cardiometabolic conditions (e.g., “diabetes mellitus”, 
“hypertension”); older patients (“aged”, “ageing”, “geriatric”); medication (e.g., “prescription”, 
“antidiabetic”, “hyperglycaemic”); and deintensification (e.g., “deprescribe”, “discontinue”, 
“deintensify” “cessation”). There were no restrictions on language. Reference lists of retrieved articles 
were manually scanned for all relevant additional studies and review articles missed by the original 
search. Full details on the search strategy are presented in Appendix 3.  
 
Data extraction and quality assessment  
One reviewer (S.K.K.) independently extracted data and performed quality assessments using a 
standardized predesigned data collection form. A second reviewer (S.S.) checked extracted data with 
that in the original articles. The titles and abstracts of all articles identified by the broad literature 
search were assessed independently by two reviewers (SS and SKK). Studies that did not meet the 
inclusion criteria were discarded. Full text of selected articles were retrieved and assessed to 
determine if the met the inclusion criteria. Those studies which met the inclusion were included in the 
review and the data were extracted independently by two reviewers (SS and SKK) using standard data 
extraction form. The quality of the studies were assessed independently by both reviewers. 
Data was extracted on study, publication date, geographical location, study design, mean age, 
percentage of males, duration of follow-up, sample size, comorbidities, concomitant medications, 
doses, frequency, duration, deintensification approach (stopping/tapering/switching), and data/risk 
estimates on benefits and harms of deintensification. Each article was assessed using the inclusion 
criteria and any disagreement regarding eligibility of an article was discussed, and agreement reached 
by consensus with a third reviewer. Additionally, in the case of multiple publications, data on the 





of observational cohort studies was assessed based on the nine-star Newcastle–Ottawa Scale (NOS),30 
a validated tool for assessing the quality of non-randomised studies, including cohort and case-control 
studies. It uses three pre-defined domains namely: selection of participants (population 
representativeness), comparability (adjustment for confounders), and ascertainment of outcomes of 
interest. The NOS assigns a maximum of four points for selection, two points for comparability, and 
three points for outcome. Nine points on the NOS reflects the highest study quality. For cross-
sectional studies, we assessed quality using the NOS modified for cross-sectional studies (Appendix 
431). A maximum score of 8 reflected the highest study quality.  
 
Statistical analysis 
The characteristics of the deintensification approaches and outcomes reported for each study were 
summarized in tables and narrative synthesis was performed. 
 
Patient and Public Involvement   
The study was supported by a patient focus group which provided input to the programme of research 
on the 9th of April 2018. Patients partnered with us for the design to refine the population to include 
other multimorbidities instead of just diabetes. They suggested that the burden of deintensification or 
deprescribing could not just be worsening of glycaemic control but admissions and falls. It is our 
intention to continue to engage the group for the dissemination of the findings 
 
Results 
Study identification and selection 
Figure 1 shows the flow of studies through the review. The literature search identified 8,547 
potentially relevant citations. After the initial screen based on titles and abstracts, 59 articles were 
selected for full text evaluation. Following detailed assessment of the full articles, 49 were excluded 





(n=16); (iii) outcomes not relevant to review (n=3); (iv) one article used the same population sample 
as another study included in the review; and (v) one was a review article.  The remaining 10 articles 
based on 10 unique studies met the inclusion criteria and were included in the review.32-41  
 
Study characteristics and study quality 
Table 1 summarises the key baseline characteristics of the included studies. Studies were published 
between 2008 and 2017. Overall, the studies involved 26,558 unique participants with type 2 diabetes. 
The majority of studies (n=3) were conducted in Europe (Sweden, and UK); three in the United 
States; and three in Asia (Japan). One study was conducted in 20 countries in Asia, Australasia, 
Europe, and North America. Only one study, with 98 patients with diabetes, was based on patients in 
Nursing Homes.32 The mean/median baseline age of participants ranged from 65.8 to 86.5 years. 
Study designs comprised of prospective cohorts (n=2); retrospective cohorts (n=2); observational 
cohorts with controls (n=2); case series (n=2); post-hoc observational analysis of a RCT (n=1); and 
cross-sectional retrospective sub-analysis of a RCT (n=1). No RCT was identified. Sample size of 
studies ranged from 5 to 11,140 participants. The average follow-up durations for studies providing 
data ranged from 3 months to 4.3 years; however, for the majority of studies, it ranged from 3 to 6 
months. Study populations comprised older patients with type 2 diabetes with comorbidities such as 
coronary heart disease (CHD) and kidney dysfunction and were on antihyperglycemic medication as 
well as blood pressure medication. Among the observational cohort studies, quality score using NOS 
ranged from 3 to 8 and that for the cross-sectional study was 4 (Appendix 5). 
 
Deintensification approaches and rates 
It was planned to synthesise risk ratios for dichotomous outcome data and mean differences for 
continuous outcomes if consistent outcomes were reported for multiple studies; however, given the 





populations, a formal meta-analysis could not be performed. We could also not make effective 
comparisons across studies because of the heterogeneity of the data.  
 
Table 2 provides details of the deintensification approaches and outcomes reported by each eligible 
study. The approaches varied and included complete withdrawal, discontinuation, reducing dosage, 
conversion, or substitution of at least one medication. However, majority of studies reported on 
complete withdrawal or discontinuation of therapy. The main reasons for considering 
deintensification was tight glycaemic control and being at risk of hypoglycaemia, which was reported 
by five studies.32,34-36,38 One study reported on the potential for deprescribing in care home residents 
with type 2 diabetes using a medicines optimisation tool, which was validated by a care home 
physician;39 though the actual deprescribing was not performed and evaluated in the study, we 
included it in this review because of its relevance to the topic. Except for one study which was based 
on blood pressure lowering therapy,40 the most common medications that were deintensified were 
antihyperglycaemic agents comprising of sulfonylureas, alpha-glucosidase inhibitors, dipeptidyl 
peptidase 4 inhibitors, and insulin. The majority of studies were before and after study designs and 
four studies compared deintensification approaches to usual care.32-34,40 Lipska and colleagues 
examined the frequency of discontinuation of antihyperglycemic agents on discharge among patients 
with diabetes admitted for acute myocardial infarction on a diabetic regimen;33 of 8751 patients 
admitted on at least 1 antihyperglycemic agent, 1170 (13.4%) were discharged off antihyperglycemic 
therapy. In a pilot study to examine the efficacy and safety of switching from subcutaneous injection 
of insulin to oral administration of vildagliptin in 20 patients with type 2 diabetes undergoing 
hemodialysis, 11 (55%) of patients switched successfully.38 In a study that investigated the 
withdrawal of all antihyperglycemics or reduction in insulin versus no change in diabetes medication 
in Swedish nursing home patients, withdrawal of the diabetic medication was successful in 24 (75%) 
patients 3 months after drug discontinuation.32 In the study that reported on the potential for 





‘Optimising Safe and Appropriate Medicine Use’ (OSAMU) (now replaced by the Improving 
Medicines and Polypharmacy Appropriateness Clinical Tool (IMPACT)42) an evidence-based tool 
developed to allow for appropriately stopping or continuing medicines in end of life; of the 67 
potentially inappropriate medications, a physician agreed that 26 (38.8%) of these could be 
discontinued without further question.39  
 
Glycaemic control 
Seven studies reported outcomes of glycaemic control after deintensification approaches (Table 2). In 
two studies that compared discontinuation or reduction in dose of antihyperglycemic medication with 
usual care, no significant differences were found in HbA1c levels.32,34 In one study,34 there was no 
significant difference in hypoglycaemia rates between the groups post-intervention.  In eight patients 
who had their hypoglycaemic medications completely withdrawn over 3-6 months and followed up 
for a year, there was no significant difference between the mean HbA1c at the point of hypoglycaemic 
medications withdrawal and at 1 year of follow-up.36 Switching α-glucosidase inhibitors from 
acarbose or voglibose to miglitol did not affect levels of HbA1c and fasting glucose in 35 Japanese 
patients; in addition, glucose fluctuations improved on switching.37 In 5 patients with type 2 diabetes 
and on haemodialysis, discontinuation of insulin and other oral hypoglycaemic agents and switching 
to liraglutide caused reduction in levels of HbA1c and hypoglycaemic episodes.41 In a retrospective 
analysis of veterans converted from glyburide to glipizide, mean HbA1c levels increased by 0.34% 1 
year after conversion; however, there was a significant reduction in hypoglycaemic events.35 
 
Other beneficial and adverse outcomes 
In two studies that evaluated switching from one antihyperglycaemic agent to another, no adverse 
events were recorded in both studies.37,38 In a study comparing patients whose antihyperglycaemic 
therapy was discontinued on discharge versus those discharged on antihyperglycaemic therapy in 





significantly between the two groups.33 In a post-hoc observational analysis of an RCT of blood 
pressure lowering and intensive glucose control in patients with type 2 diabetes, permanent 
discontinuation of blood pressure lowering medication during the study period compared to 
continuing administration of randomised medications was associated with increased risk of macro- 
and micro-vascular events.40 When insulin and other oral hypoglycaemic medications were switched 




Three studies reported mortality outcomes after deintensification approaches (Table 2). Two studies 
reported that discontinuation of antihyperglycaemic or blood pressure lowering therapy was 
associated with an increased risk of mortality.33,40 In the study by Sjoblom and colleagues, which 
compared complete withdrawal or reduction in dose of antihyperglycemic medication with usual care, 
there was no significant difference in the risk of mortality for the deintensification group compared to 




Using a systematic review, we have assessed deintensification approaches and rates and the associated 
benefits and harms from available published observational and interventional studies conducted in 
older people with type 2 diabetes, including those with comorbidities such as CHD, hypertension, and 
kidney disease. Deintensification approaches identified included complete withdrawal, 
discontinuation, reducing dosage, conversion, or substitution of at least one medication; however, 
majority of studies were based on complete withdrawal or discontinuation of antihyperglycaemic 
medication. Deintensification rates varied based on the approach but generally ranged from 13.4% to 





reported no deterioration in HbA1c levels or hypoglycaemic episodes in the patient populations. On 
adverse events and mortality, no significant differences were observed between the comparison 
groups in the majority of studies.  
 
Comparison with previous studies 
We identified only one systematic review which attempted to synthesize evidence on studies 
evaluating the effects of deprescribing versus continuing antihyperglycemics in older adults with type 
2 diabetes. Black and colleagues included only two studies in their review and concluded that there 
was limited and low-quality evidence on deprescribing antihyperglycaemic medications.43 We have 
adopted a broader approach which involved assessing deintensification approaches and their benefits 
and harms in older patients with type 2 diabetes with or without comorbidities. Indeed, the evidence is 
limited and of low quality, but based on the available evidence, our findings show that 
deintensification may be feasible and its benefits generally outweigh the harms. We have also 
identified some gaps in the evidence. None of the studies provided specific guidance on how patients 
were identified for the deintensification approach; however, a few studies reported considering 
deintensification based on patients with tight glycaemic control or at high risk for hypoglycaemia. 
Though one of the included studies did not specifically evaluate a deintensification approach, the 
authors assessed and validated a medicines optimisation tool which was found to be appropriate in 
allowing pharmacists to identify medicines eligible for deprescribing in care home residents with type 
2 diabetes, thus reducing polypharmacy and potentially adverse events.39 Finally, though 
discontinuation of therapy was the most common deintensification approach reported, it was difficult 
to conclude from the findings that a particular approach was associated with more benefits. 
 
Implications of findings 
For several decades, clinical practice guidelines for glycaemic control have focused on intensifying 





However, it appears this overtreatment or treatment intensification is not harmless or associated with 
more benefits. A number of RCTs have shown that intensive glycaemic control directed at lower 
HbA1c targets are associated with only minor cardiovascular benefits but increased adverse events 
such as mortality.46 Evidence shows that older people with type 2 diabetes and other comorbidities are 
being overtreated with drugs that cause hypoglycaemia.20-22,47 Hambling and colleagues observed that 
older people, including those with comorbidities such as CKD or dementia, were managed to similar 
intensive thresholds as those without CKD or dementia.47 These elderly patients are especially 
vulnerable to hypoglycaemic episodes and other adverse events such as fractures, head injuries, CVD, 
or even death;9,11,12 given predisposing factors such as advanced age, frailty, long duration of diabetes, 
polypharmacy, and comorbidities such as CKD and cognitive impairment.9,15,48,49 Intensive treatment 
with antihyperglycaemic medication in these patients doubles the risk of hypoglycaemia.50 In 
addition, only few older patients with type 2 diabetes and complex comorbidities actually gain 
substantial benefit from intensive management.51,52 The need for deintensification approaches is 
therefore of substantial relevance in healthcare. Indeed, deintensification or deprescribing is already 
becoming an essential part of prescribing when managing patients with multiple conditions and end of 
life.26,27,53 Available evidence from our review suggests that deintensification is associated with more 
benefits than harms and it is feasible. However, though discontinuation or complete withdrawal of 
antihyperglycaemic therapy is very commonly used, it is uncertain if it is associated with more 
benefits compared with other approaches. Furthermore, guidance is needed on how to identify patients 
for deintensification and which approaches will be suitable for a particular patient. 
Strengths and limitations 
Some strengths and limitations of this study merit careful consideration. Compared to the only 
relevant previous review which only evaluated the effects of deprescribing antihyperglycaemic 
medications in older adults with type 2 diabetes,43 our review was more detailed and focussed on 
deintensification in patients with or with comorbidities. Our literature search was detailed and 





majority were inherent to the included studies and not the actual review. The data was sparse and 
heterogenous, hence we were unable to pool data as originally planned in our published protocol 
(CRD42018102853); however, we were able to summarise the evidence according to identified 
consistent themes. We included a diversity of study designs such as observational cohorts, case series, 
and post-hoc observational analysis of RCTs, and these were generally not of high methodological 
quality. Majority of studies were of short follow-up durations of a few months, which precludes 
inadequate evaluation of the impact of an intervention. Furthermore, studies selectively reported 
outcomes and did not report results in a manner that could assist clinicians in making decisions. Given 
these limitations, the findings should be interpreted with caution.  
 
In conclusion, available but limited evidence based on mixed study designs suggest that the benefits 
of deintensification outweighs the harms in older people with type 2 diabetes with or without 
comorbidities. The data also suggests deprescribing is feasible. There are still some unanswered 
questions. There is limited information to guide which deprescribing approaches to use in order to 
achieve safe individual targets in older patients. The appropriate glycaemic control targets in such 
patients are also uncertain. Guideline bodies have started to recognise the harms of overtreatment in 
older patients with diabetes and several recommendations have been made to reflect the heterogeneity 
of these patients. The American Diabetes Association (ADA) and the European Association for the 
Study of Diabetes (EASD) guidelines for diabetes treatment recommend an individualised approach 
based on the preference of the patient, comorbidities, severity of diabetes-related complications, and 
life expectancy.44 In recent guidelines, the ADA, the American Geriatrics Society, and the American 
Board of Internal Medicine’s Choosing Wisely campaign recommend target HbA1c levels of 7.5% or 
8.0% for older patients and those with limited life expectancy.54-56 Given the heterogeneity of patients 
with diabetes, further research is warranted on which deintensification approaches are appropriate and 







1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and 
its complications. Nat Rev Endocrinol. 2018;14(2):88-98. 
2. Patel P, Macerollo A. Diabetes mellitus: diagnosis and screening. Am Fam Physician. 
2010;81(7):863-870. 
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident 
cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 
individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233-240. 
4. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral 
antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 
2010;33(8):1859-1864. 
5. Khunti K, Davies MJ. Clinical inertia-Time to reappraise the terminology? Prim Care 
Diabetes. 2017;11(2):105-106. 
6. Khunti K, Davies MJ. Clinical inertia versus overtreatment in glycaemic management. Lancet 
Diabetes Endocrinol. 2018;6(4):266-268. 
7. Abdelhafiz AH, Rodriguez-Manas L, Morley JE, Sinclair AJ. Hypoglycemia in older people - 
a less well recognized risk factor for frailty. Aging Dis. 2015;6(2):156-167. 
8. Lee SJ, Boscardin WJ, Stijacic Cenzer I, Huang ES, Rice-Trumble K, Eng C. The risks and 
benefits of implementing glycemic control guidelines in frail older adults with diabetes 
mellitus. J Am Geriatr Soc. 2011;59(4):666-672. 
9. Rajendran R, Hodgkinson D, Rayman G. Patients with diabetes requiring emergency 
department care for hypoglycaemia: characteristics and long-term outcomes determined from 
multiple data sources. Postgrad Med J. 2015;91(1072):65-71. 
10. Nicolucci A, Pintaudi B, Rossi MC, et al. The social burden of hypoglycemia in the elderly. 
Acta Diabetol. 2015;52(4):677-685. 
11. Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with 
cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based 
study. Diabetes Care. 2013;36(4):894-900. 
12. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk 
of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and 
type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316-322. 
13. Farmer AJ, Brockbank KJ, Keech ML, England EJ, Deakin CD. Incidence and costs of severe 
hypoglycaemia requiring attendance by the emergency medical services in South Central 
England. Diabet Med. 2012;29(11):1447-1450. 
14. Newton CA, Adeel S, Sadeghi-Yarandi S, et al. Prevalence, quality of care, and complications 






15. Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive 
impairment in elderly patients treated with glucose-lowering agents: a systematic review and 
meta-analysis. Diabetes Obes Metab. 2016;18(2):135-141. 
16. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). 
Geneva, Switzerland: World Health Organization;1977. 
17. World Health Organization. International Statistical Classification of Diseases, 10th Revision 
(ICD-10). Geneva, Switzerland: World Health Organization;1992. 
18. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical 
Activity and Cardiovascular Health. Jama. 1996;276(3):241-246. 
19. Zaccardi F, Davies MJ, Dhalwani NN, et al. Trends in hospital admissions for hypoglycaemia 
in England: a retrospective, observational study. Lancet Diabetes Endocrinol. 2016;4(8):677-
685. 
20. Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of 
diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 
2015;175(3):356-362. 
21. Penfornis A, Fiquet B, Blickle JF, Dejager S. Potential glycemic overtreatment in patients 
>/=75 years with type 2 diabetes mellitus and renal disease: experience from the observational 
OREDIA study. Diabetes Metab Syndr Obes. 2015;8:303-313. 
22. Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic 
medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 
2015;38(4):588-595. 
23. Hambling CE, Khunti K, Cos X, et al. Factors influencing safe glucose-lowering in older 
adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) 
Glycemic Goals for older people: A position statement of Primary Care Diabetes Europe. 
Prim Care Diabetes. 2019. 
24. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging de fi nition of 
'deprescribing' with network analysis: implications for future research and clinical practice. Br 
J Clin Pharmacol. 2015;80(6):1254-1268. 
25. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of 
deprescribing. JAMA Intern Med. 2015;175(5):827-834. 
26. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of 
multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 
2010;170(18):1648-1654. 
27. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication 
appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605-609. 
28. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in 






29. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews 
and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. 
30. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the 
quality of nonrandomised studies in meta-analyses. 2011. 
www.ohri.ca/programs/clinical_epidemiology/oxford.asp.; 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed 10 March 2015. 
31. Kunutsor SK, Apekey TA, Laukkanen JA. Association of serum total osteocalcin with type 2 
diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of 
observational evidence. Eur J Epidemiol. 2015;30(8):599-614. 
32. Sjoblom P, AndersTengblad, Lofgren UB, et al. Can diabetes medication be reduced in 
elderly patients? An observational study of diabetes drug withdrawal in nursing home patients 
with tight glycaemic control. Diabetes Res Clin Pract. 2008;82(2):197-202. 
33. Lipska KJ, Wang Y, Kosiborod M, et al. Discontinuation of antihyperglycemic therapy and 
clinical outcomes after acute myocardial infarction in older patients with diabetes. Circ 
Cardiovasc Qual Outcomes. 2010;3(3):236-242. 
34. Aspinall SL, Zhao X, Good CB, et al. Intervention to decrease glyburide use in elderly 
patients with renal insufficiency. Am J Geriatr Pharmacother. 2011;9(1):58-68. 
35. Skoff RA, Waterbury NV, Shaw RF, Egge JA, Cantrell M. Glycemic control and 
hypoglycemia in Veterans Health Administration patients converted from glyburide to 
glipizide. J Manag Care Pharm. 2011;17(9):664-671. 
36. Abdelhafiz AH, Chakravorty P, Gupta S, Haque A, Sinclair AJ. Can hypoglycaemic 
medications be withdrawn in older people with type 2 diabetes? Int J Clin Pract. 
2014;68(6):790-792. 
37. Hariya N, Mochizuki K, Inoue S, et al. Switching alpha-glucosidase inhibitors to miglitol 
reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 
diabetic Japanese patients. Drugs R D. 2014;14(3):177-184. 
38. Yoshida N, Babazono T, Hanai K, Uchigata Y. Switching from subcutaneous insulin injection 
to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study. 
Int Urol Nephrol. 2016;48(8):1349-1355. 
39. Andreassen LM, Kjome RL, Solvik UO, Houghton J, Desborough JA. The potential for 
deprescribing in care home residents with Type 2 diabetes. Int J Clin Pharm. 2016;38(4):977-
984. 
40. Hirakawa Y, Arima H, Webster R, et al. Risks associated with permanent discontinuation of 
blood pressure-lowering medications in patients with type 2 diabetes. J Hypertens. 
2016;34(4):781-787. 
41. Kondo M, Toyoda M, Kimura M, Ishida N, Fukagawa M. Favorable Effect on Blood Volume 
Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy 
to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in 





42. Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-term follow-up for mortality and 
cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD 
trial). J Clin Endocrinol Metab. 2012;97(2):614-622. 
43. Black CD, Thompson W, Welch V, et al. Lack of Evidence to Guide Deprescribing of 
Antihyperglycemics: A Systematic Review. Diabetes Ther. 2017;8(1):23-31. 
44. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 
diabetes, 2015: a patient-centered approach: update to a position statement of the American 
Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 
2015;38(1):140-149. 
45. Mosenzon O, Pollack R, Raz I. Treatment of Type 2 Diabetes: From "Guidelines" to "Position 
Statements" and Back: Recommendations of the Israel National Diabetes Council. Diabetes 
Care. 2016;39 Suppl 2:S146-153. 
46. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose 
lowering treatment on all cause mortality, cardiovascular death, and microvascular events in 
type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169. 
47. Hambling CE, Seidu SI, Davies MJ, Khunti K. Older people with Type 2 diabetes, including 
those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea 
or insulin therapies. Diabet Med. 2017;34(9):1219-1227. 
48. Abdelhafiz AH, Koay L, Sinclair AJ. The effect of frailty should be considered in the 
management plan of older people with Type 2 diabetes. Future Sci OA. 2016;2(1):FSO102. 
49. Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic 
hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol. 
2015;52(5):845-853. 
50. McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND. Intensive Treatment and 
Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Intern Med. 
2016;176(7):969-978. 
51. Blaum C, Cigolle CT, Boyd C, et al. Clinical complexity in middle-aged and older adults with 
diabetes: the Health and Retirement Study. Med Care. 2010;48(4):327-334. 
52. Cigolle CT, Kabeto MU, Lee PG, Blaum CS. Clinical complexity and mortality in middle-
aged and older adults with diabetes. J Gerontol A Biol Sci Med Sci. 2012;67(12):1313-1320. 
53. Todd A, Holmes HM. Recommendations to support deprescribing medications late in life. Int 
J Clin Pharm. 2015;37(5):678-681. 
54. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 
diabetes: a patient-centered approach: position statement of the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes (EASD). 
Diabetes Care. 2012;35(6):1364-1379. 
55. Workgroup AGSCW. American Geriatrics Society identifies five things that healthcare 





56. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. J Am 







Figure 1. Selection of studies included in the review 
 
 
8547 Potentially relevant citations identified
From MEDLINE, EMBASE, Cochrane 
database and reference list of relevant 
studies
8488 excluded on the basis of title 
and/ or abstract
49 Articles excluded due to:
28 Populations not relevant to review
16 Intervention not relevant
3 Outcomes not relevant to review
1 Duplicate
1 Review article
10 Articles included, based on 10 
studies






































Table 1. Baseline characteristics of studies included in review 
Lead Author, Publication Date  
 









































           
Sjoblom, 2008 NR (Nursing homes) Sweden Prospective cohort 
with controls 
Elderly patients with T2DM with HbA1c ≤ 6.0% 2006 84.1 41.8 6 months 98 4 
Lipska, 2010 NHCP (Medicare 
beneficiaries) 
USA Retrospective cohort Older patients with diabetes after AMIs and on at least 
1 antihyperglycaemic agent 
1998-2001 76.5 47.2 1 year 8751 8 
Aspinall, 2011 Veteran Affairs Database USA Retrospective cohort 
with controls 
Community dwelling veterans 2007-2008 77.0 99.5 5 months 6254 7 
Skoff, 2011 VHA USA Retrospective cohort Elderly diabetes veterans with renal dysfunction 2008-2010 74.0 99.3 1 year 141 5 
Abdelhafiz, 2014 NR (Outpatient health 
clinic) 
UK Case series Older patients with diabetes NR 86.5 25 1 year 8 NA 
Hariya, 2014 NR (Healthcare setting) Japan Prospective cohort 
study 
Patients with T2DM 2007-2008 65.8 48.6 3 months 35 3 
Yoshida, 2016 NR (Healthcare setting) Japan Prospective cohort 
study 
Patients with T2DM on haemodialysis 2010-2011 66.0 55.0 24 weeks 20 3 
Andreassen, 2016 CAREMED (clinical trial) UK Cross-sectional 
retrospective sub-
analysis of a RCT 
Elderly patients with T2DM NR 86.0 51.4 NA 106 4 
Hirakawa, 2016 ADVANCE 20 countries Post-hoc 
observational 
analysis of RCT 
Patients with T2DM on blood pressure lowering and 
intensive glucose control 
2001-2003 65.8 57.5 4.3 years 11,140 8 
Kondo, 2017 NR (Healthcare setting) Japan Case series Patients with T2DM on haemodialysis 2011-2012 67.6 80.0 3 months 5 NA 
 
AMI, acute myocardial infarction; CHD, coronary heart disease; LDL-C, low density lipoprotein cholesterol; NA, not applicable; NHCP, National Heart Care Project; NR, not reported; RCT, randomised controlled 






Table 2. Deintensification approaches and outcomes in eligible studies 
Lead Author, 


































         
Sjoblom, 2008 Patients with HbA1c ≤ 6.0% and 
on antidiabetic drugs or insulin, or 
both in combination, were invited 
to participate in the diabetes 
medication withdrawal 
Plasma glucose was measured 
on 3 consecutive days before 
medication withdrawal. 
Complete withdrawal of oral 
anti-diabetic drugs, complete 
insulin withdrawal when doses 
were 20 units/day and reduced 
by half in patients on more than 
20 units/day 
No change in diabetes 
medication 
32 / 66 Withdrawal of the 
diabetic medication was 
successful in 24 (75%) 
patients 3 months after 
drug discontinuation 
HbA1c levels: 5.8% (Intervention arm): 
6.6% (Control arm) at 6 months 
 5 out of 32 patients 
(16%) in deprescribing 
group compared to 14 
out of 66 (21%) in the 
non-intervention group 
died: 0.74 (0.29-1.87) 
Lipska, 2010 Reasons behind the 
discontinuation of 
antihyperglycemic therapy was 
not evaluated 
Discontinuation of 
antihyperglycemic agents on 
discharge. Was based on 





1170 / 7581 13.4% discharged off 
antihyperglycemic 
therapy 
NR Readmissions did not differ between the two 
groups 
Discontinuation of 
therapy was associated 
with HR (95% CI) of 
1-year mortality of 
1.29 (1.15-1.45) 
Aspinall, 2011 Patients considered at increased 
risk of hypoglycaemia – were on 
glyburide with a calculated 
creatinine clearance of < 50 
ml/min 
Discontinuation of glyburide. 
Information regarding risk of 
hypoglycaemia in older persons 
on glyburide and instructions 
for switching to alternative 
agent provided to pharmacists, 
who could then contact 
patients’ physicians to 
deprescribe 
Received usual care 4368 / 1886 During the study period, 
glyburide was 
discontinued in 71.5% 
(3123/4368) of the 
patients in the targeted 
cohort and in 56.0% 
(1057/1886) of the 
nontargeted cohort. 
No significant difference in HbA1c levels 
was found between the group of patients 
who discontinued glyburide and those 
who continued taking this medication. No 
significant difference was observed in the 
rates of hypoglycaemia post-intervention 
between the intervention and control 
groups 
NR NR 
Skoff, 2011 Patients considered at increased 
risk of hypoglycaemia – were on 
glyburide with renal dysfunction 
Conversion from glyburide to 
glipizide 
NA NA NA Increase in HbA1c level of 0.34% at 1 
year after conversion. Hypoglycaemia was 
confirmed in 44 (31.2%) patients during 
glyburide treatment and in 18 (12.8%) 
patients during treatment with glipizide 
Liver and renal functions were similar at the 
point of medication withdrawal compared 










































Abdelhafiz, 2014 Tight glycaemic control (HbA1c ≤ 
6%) was the main reason for 
medication withdrawal in two 
patients, while recurrent episodes 
of hypoglycaemia were the main 
reason in the other six patients 
patients 
Complete withdrawal of 
hypoglycaemic medication 
over 3-6 months 
NA NA NA No deterioration of glycaemic control 
over the 1-year follow-up period. No 
significant difference between the mean 
HbA1c at the point of hypoglycaemic 
medications withdrawal and at 1 year of 
follow-up. 
NR NR 
Hariya, 2014 Patients with HbA1c values 
ranging from 6.9-8.3% being 
treated with the highest approved 




inhibitors from acarbose or 
voglibose to miglitol and 
continued for 3 months 
NA NA NA Switch did not affect levels of HbA1c and 
fasting glucose. Glucose fluctuations were 
improved on switch. 
No adverse events recorded NR 
Yoshida, 2016 Patients on haemodialysis and 
receiving subcutaneous insulin 
injection 
Switching from subcutaneous 
injection of insulin to oral 
administration of a DPP-4 
inhibitor. Oral vildagliptin at a 
low dose was started on the day 
insulin injection were 
discontinued 
NA NA 11 (55%) patients 
switched successfully  
Glycated albumin was < 1.5% during the 
post switch 
No adverse events recorded NR 
Andreassen, 2016 NA Potential for deprescribing NA NA Out of the total of 67 
PIMs, the physician 
agreed that 26 of these 
could be discontinued 
without further question 
(38.8 %). 
NA NR NR 
Hirakawa, 2016 Due to adverse effects, inability, 
or unwillingness to continue with 
medication 
Permanent discontinuation of 
BP lowering medication. Based 
on a retrospective analysis of a 
database 
Those who did not 
discontinue 
1557 / 9583 14% NR Discontinuation of BP lowering medication 
was associated with HR (95% CI) of 
macrovascular events 3.23 (2.75-3.79); 
microvascular events 1.38 (1.11-1.71); and 
combined macrovascular and microvascular 
events 2.24 (1.96-2.57)  
Discontinuation of BP 
lowering medication 
was associated with 
HR (95% CI) of 
mortality 7.99 (6.92-
9.21); 
Kondo, 2017 Patients on haemodialysis Discontinuation of insulin and 
switching to liraglutide.  
NA NA NA Reduction in levels of HbA1c. Reduction 
in hypoglycaemic episodes 
Significant decrease in cardiothoracic ratio 
on chest radiography. Improved quality of 
life in more than half of patients 
NR 
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No Checklist item 
Reported 
on page No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, 
limitations, conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 3 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if 
available, provide registration information including registration number 
4 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as 
years considered, language, publication status) used as criteria for eligibility, giving rationale 
4 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched 
4 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated 
Appendix 3 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators 
5 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
5 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data 
synthesis 
5, Appendix 5 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). 6 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
6 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication 
bias, selective reporting within studies) 
5-6 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified 
NA 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram 
6 and Figure 1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, 
follow-up period) and provide the citations 
7, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 
12). 
7, Table 1 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for 
each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
7-10 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency 7-10 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) 7, Table 1; 
Appendix 5 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) 





24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
10 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 
incomplete retrieval of identified research, reporting bias) 
12 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and 






Appendix 2. MOOSE checklist  
 
Deintensification in older patients with type 2 diabetes: a systematic review 
of approaches, rates and outcomes 
 
 
Criteria Brief description of how the criteria were handled in the 
review 
Reporting of background   
 Problem definition Recognising some harms of overtreatment, guideline bodies 
recommend de-intensification or deprescribing in older patients with 
diabetes. It is uncertain whether the benefits of deintensification 
outweighs the harms in these patients. We conducted a systematic 
review of published evidence, to assess deintensification approaches 
and rates and evaluate the harms and benefits of deintensification 
with antidiabetic medication and other therapies amongst older 
people (≥ 65 years) type 2 diabetes with or without cardiometabolic 
conditions. 
 Hypothesis statement Circulating levels of OC are associated with cardiovascular outcomes 
 Description of study outcomes Admission rates 
Hospitalisations 
Complications (e.g., hyperglycaemia, DKA, Hyperglycaemic 
Hyperosmolar Nonketotic Coma (HONK)) 
Falls 
Mortality 
Quality of life 
Patient satisfaction 
 Type of exposure  Deintensification approaches (stopping drug treatment entirely, 
reducing dose, gradual tapering, or substitution) of at least one 
medication 
 Type of study designs used Observational (cross-sectional, prospective or retrospective case 
control, prospective cohort, retrospective cohort, case-cohort, or 
nested-case control) studies and clinical trials (randomised controlled 
trials including cluster and pragmatic trials and non-randomised 
controlled trials) 
 Study population (i) included elderly patients (≥ 65 years) with type 2 diabetes and/or 
other cardiometabolic conditions (e.g., cardiovascular disease, 
hypertension) who were taking antidiabetic medication and plus 
other therapies for type 2 diabetes and other cardiometabolic 
conditions; (ii) reported deintensification approaches (stopping drug 
treatment entirely, reducing dose, gradual tapering, or substitution); 
and/or (iii) reported outcomes such as admission rates, 
hospitalisations, complications, quality of life, and patient 
satisfaction. The 65 years and older cutoff will apply if the average 
age of study participants age is 65 years or older; more than 75% of 
study participants are aged 65 years and older; or data from 
participants aged 65 years and older can be extracted from the 
study. 
 
Reporting of search strategy should 
include 
 
 Qualifications of searchers Samuel Seidu, MD; Setor Kunutsor, PhD 
 Search strategy, including time 
period included in the synthesis and 
keywords 
Time period: from inception of MEDLINE and EMBASE to 02 October 
2018.  
Search strategy: 
The detailed search strategy can be found in Appendix 3. 
 Databases and registries searched MEDLINE, Embase and Cochrane databases 
 Search software used, name and 
version, including special features 
OvidSP was used to search Embase 
EndNote 9 used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  





excluded, including justifications The citation list for excluded studies is available upon request. 
 Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language 
 Method of handling abstracts and 
unpublished studies 
Not applicable 
 Description of any contact with 
authors 
Not applicable 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be 
tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, exposure, and outcomes 
 Assessment of confounding Not applicable  
 Assessment of study quality, 
including blinding of quality 
assessors; stratification or regression 
on possible predictors of study 
results 
Study quality was assessed based on the nine-star Newcastle–
Ottawa Scale using pre-defined criteria namely: population 
representativeness, comparability (adjustment of confounders), 
ascertainment of outcome and the Cochrane risk of bias tool 
 Assessment of heterogeneity Limited data precluded assessment of heterogeneity 
 Description of statistical methods in 
sufficient detail to be replicated 
Not applicable 
 Provision of appropriate tables and 
graphics 
Table 1; Figure 1 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
NA 
 Table giving descriptive information 
for each study included 
Table 1  
 Results of sensitivity testing 
 
NA 
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary 
estimates 
Reporting of discussion should include  
 Quantitative assessment of bias The systematic review is limited in scope, as it involves published 
data. 
 
 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria 
in methods section. 
 Assessment of quality of included 
studies 
Brief discussion included in ‘Methods’ section 
Reporting of conclusions should 
include 
 
 Consideration of alternative 
explanations for observed results 
Findings should be interpreted with caution due to limited study and 
quality of study designs 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend definitive clinical trials 







Appendix 3. MEDLINE literature search strategy 
 
1     exp Diabetes Mellitus, Type 2/ (120600) 
2     exp Diabetes Mellitus/ (397262) 
3     NIDDM.mp. (6891) 
4     T2DM.mp. (16195) 
5     exp Aged/ (2910982) 
6     nursing home resident*.mp. (6065) 
7     elderly.mp. (232319) 
8     exp Aging/ (233498) 
9     65 year.mp. (9083) 
10     exp Geriatrics/ (29074) 
11     older adult.mp. (6126) 
12     older people.mp. (24923) 
13     medication.mp. (218052) 
14     exp Prescriptions/ (32535) 
15     exp Hypoglycemic Agents/ad, ae, th [Administration & Dosage, Adverse Effects, Therapy] 
(37918) 
16     antihyperglycemic.mp. (2511) 
17     exp Metformin/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic Use] (8753) 
18     exp Sulfonylurea Compounds/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic 
Use] (7667) 
19     meglitinides.mp. (145) 
20     exp Glyburide/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic Use] (2001) 
21     exp Thiazolidinediones/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic Use] 
(5134) 
22     glitazones.mp. (592) 
23     exp Dipeptidyl-Peptidase IV Inhibitors/ad, ae, tu [Administration & Dosage, Adverse Effects, 
Therapeutic Use] (2576) 
24     exp Glucagon-Like Peptides/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic 
Use] (2029) 
25     exp Insulin/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic Use] (37615) 
26     exp Insulin, Long-Acting/ or exp Insulin, Short-Acting/ (4659) 
27     exp Antihypertensive Agents/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic 
Use] (110119) 
28     exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ad, ae, tu [Administration & Dosage, 
Adverse Effects, Therapeutic Use] (26195) 
29     statin.mp. (20163) 
30     exp Platelet Aggregation Inhibitors/ad, ae, tu [Administration & Dosage, Adverse Effects, 
Therapeutic Use] (57831) 
31     Blood Platelet Antiaggregant*.mp. (0) 
32     Platelet Inhibitor*.mp. (1325) 
33     exp Cardiovascular Agents/ad, ae, tu [Administration & Dosage, Adverse Effects, Therapeutic 
Use] (399102) 





35     deintensification.mp. (86) 
36     de-intensify.mp. (12) 
37     exp Deprescriptions/ (193) 
38     withdraw*.mp. (123124) 
39     ceas*.mp. (22534) 
40     cessation.mp. (78878) 
41     discontinu*.mp. (114282) 
42     reduc*.mp. (3152639) 
43     withheld.mp. (4417) 
44     substitut*.mp. (346366) 
45     stop*.mp. (122161) 
46     eliminat*.mp. (300594) 
47     taper*.mp. (18862) 
48     1 or 2 or 3 or 4 (402270) 
49     5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (3137965) 
50     13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 
29 or 30 or 31 or 32 or 33 or 34 (726827) 
51     35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 (3991874) 
52     48 and 49 and 50 and 51 (6997) 
53     limit 52 to humans (6975) 
 
************************************************************** 











The methodological quality score is based on New-Castle Ottawa Quality Scale and is adapted for this 
review. Maximum of one star can be awarded for each item in Selection and Outcome categories. A 
maximum of two stars can be given for Comparability items. 
 
Cut-off scores 
Low methodological quality 0-3 stars 
Moderate methodological quality 4-6 stars 
High methodological quality 7-8 stars (>75%) 
 
Category 1: Selection 
 
1. Representativeness of the sample 
(a) Truly representative if the sample is randomly derived from the general population with sample 
size of >100 subjects * 
(b) Somewhat representative sample from the population with sample size of >100* 
(c) Selected group of users (e.g., nurses, volunteers) 
(d) No description of the derivation of the cases. 
 
2. Non-respondents 
(a) Comparability between respondents and non-respondents characteristics is established, and the 
response rate is satisfactory* 
(b) The response rate is unsatisfactory, or the comparability between respondents and non-
respondents is unsatisfactory 
(c) No description of the response rate or the characteristics of the responders and the non-
responders 
 
3. Adequate definition of exposure 
(a) Yes, according to a clear and widely used definition * 
(b) Yes, from record linkage or based on self-reports 
(c) No description. 
 
4. Ascertainment of exposure 
(a) Secure record* 
(b) Written self-report 
(c) No description 
 
 
Category 2: Comparability 
 
5. Comparability on the basis of the design/analysis 
(a) Study controls for age, sex, or BMI* 
(b) Study controls for any additional factor: Smoking status, education, alcohol intake, physical 
activity, lipids, or blood pressure)* 
 
 
Category 3: Outcome  
 
6. The study used a precise definition of outcome and valid and reliable method (individually for each 
relevant outcome) 
 
7. Assessment of outcome  
(a) Independent blind assessment (reference to medical records)* 
(b) Record linkage (coded by ICD on database records)* 
(c) Self-report. 
(d) No description. 
 





(a) The statistical test used to analyse the data is clearly described and appropriate, and the 
measurement of the association is present, including confidence intervals and the probability level (p-
value)* 





Appendix 5. Methodological quality of eligible studies using the Newcastle 
Ottawa Quality Scale 
 
 








Overall Quality Score 
(Maximum=9) 
Sjoblom, 2008 3 0 1 4 
Lipska, 2010 3 2 3 8 
Aspinall, 2011 3 2 2 7 
Skoff, 2011 3 0 2 5 
Hariya, 2014 2 0 1 3 
Yoshida, 2016 2 0 1 3 
Andreassen, 2016* 2 0 2 4 
Hirakawa, 2016 3 2 3 8 
 
*, this was based on Modified Newcastle Ottawa Quality Scale for cross-sectional studies as described 
in Appendix 4. 
 
 
